Home
overview
Gene therapy is a novel approach to treat, cure and ultimately prevent disease by changing the expression of a person’s gene. Gene therapy is still in the early experimental stages, due to the many factors that have prevented researchers from developing successful techniques. This conference aims to address these key factors as the potential for gene therapy continues to grow. As the first gene therapy products are expected to hit the market by 2003, this conference aims to cover the key issues and discuss them both in theoretical terms and through practical current case studies.

The topics covered at this Gene therapy conference will include practical issues such as delivery systems and diagnosing genetic defects. It will also cover in detail the application of gene therapy in the various therapeutic areas such as cancer, cardiovascular disease and HIV infection. Commercial issues, legal issues and ethical issues will also be discussed as well as the current market situation in order to keep all those involved in gene therapy up to date with the current issues and concepts.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Dominic Wells

Dr Dominic Wells, Reader in Transgenic Biology, Imperial College of Science, Technology & Medicine

9:10 OVERVIEW

Dr Andrew Mountain

Dr Andrew Mountain, Research Director, Cobra Therapeutics

  • The importance of gene therapy
  • Exvivo and invivo approaches
  • Introduction to main vector types
  • Clinical history and status
  • Problems and progress in transgene expression
  • Issues for further development of gene therapy
  • 9:40 GENE THERAPY PRODUCTS

    Dr Douglas Jolly

    Dr Douglas Jolly, Chief Executive Officer, BioMedica

  • What is gene therapy good for?
  • Retro and lentiviral vectors - learn from the past, but its not the future
  • Neurological disease as a target
  • Putting lentivectors in the clinic
  • Why buy gene therapy now?
  • 10:20 LOCALIZED PRODUCTION OF THERAPEUTIC PROTEINS AT THE SITE OF DISEASE

    Dr Richter King

    Dr Richter King, Vice President, Research, GenVec

  • Advantages of using local delivery for the generation of gene therapy products
  • Adenovector technology for local gene delivery
  • Products for important medical needs based on local gene therapy
  • Targeted adenovectors to expand gene therapy product discovery
  • 11:00 Morning Coffee

    11:20 UNDERSTANDING THE VECTOR-GENE-DISEASE RELATIONSHIP

    Dr James McArthur

    Dr James McArthur, Principal Scientist, Senior Director, Preclinical Biology and Immunology, Cell Genesys

  • AAV immunity and the route of administration
  • Lentiviral vector immunity and the antigen presenting cell
  • Adenoviral vector pathology and the target issue
  • 12:00 HURDLES IN GENE THERAPY DELIVERY

    Dr Ronald Vogels

    Dr Ronald Vogels, Senior Scientist, Crucell

  • Hurdles for applications of adenovirus type-5 based vectors
  • Modifications to adenoviruses to avoid neutralising antibodies
  • Modifications to adenoviruses to improve tissue - specific gene delivery
  • Safe and cost-effective manufacturing of capsid - modified adenoviral vectors
  • 12:40 Networking Lunch

    14:00 TRANZVECTOR - A NEXT GENERATION LENTIVIRAL VECTOR WITH ENHANCED SAFETY

    Dr Ram Ramabhadran

    Dr Ram Ramabhadran, Senior Vice President, Research & Development, Tranzyme

  • Design and advantages of TranzVector
  • Novel approaches to therapies for neuro-opthalmic diseases
  • Relevance of TranzVector in neuro-ophthalmic diseases
  • Identification of therapeutic genes and validation as targets
  • Development of cell and animal models
  • Therapeutic applications
  • 14:40 THE FUTURE OF PROTEIN DELIVERY

    Dr Albert Rauch

    Dr Albert Rauch, Managing Director, Ladenburg Thalmann

  • Underappreciated and misunderstood
  • Marching towards commercialisation
  • The right vector, for the right gene, for the right disease
  • Genomics, providing more proteins to deliver
  • 15:20 Afternoon Tea

    15:40 ALTERNATIVE VECTORS FOR GENE THERAPY

    Dr Alain Rolland

    Dr Alain Rolland, Senior Vice President, Preclinical Research & Development, Valentis

  • From local applications to systemic gene delivery
  • Noncondensing polymers for delivery to solid tissues
  • Polymeric systems and electroporation for producing systemic proteins
  • Liposome-mediated gene transfer in oncology
  • Effectiveness of synthetic delivery systems in preclinical models
  • Safety and utility in gene therapy
  • 16:20 GENE DELIVERY AND VACCINES

    Dr Christian Hofmann

    Dr Christian Hofmann, Vice President, Vector Development, DeveloGen

  • Pre-existing immunity against human viral vectors
  • Non-human viral vectors for gene delivery
  • Efficiency and tropism in animal models
  • From potential to meaningful therapeutic applications
  • Prophylactic and therapeutic vaccines
  • Virus-based gene discovery engines
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Hardev Pandha

    Dr Hardev Pandha, Senior Lecturer in Medical Oncology, St George’s Hospital Medical School

    9:10 DISEASE TARGETED RESEARCH

    Dr Jack Reich

    Dr Jack Reich, Founder, Formerly Chairman & Chief Executive Officer, Collateral Therapeutics

  • Non-surgical cardiovascular angiogenesis
  • Invivo application
  • Dual recombinant angiogenic growth factor
  • Problems in treating cardiovascular diseases
  • Congestive heart failure
  • Possibilities for prevention
  • 9:40 PRE-CLINICAL AND CLINICAL STUDIES WITH ONYX-015: CURRENT PROGRESS AND FUTURE POTENTIAL

    Dr Scott Freeman

    Dr Scott Freeman, Vice President, Clinical Development, Onyx Pharmaceuticals

  • Replacement of tumour suppressor genes
  • Abnormalities in the P53 function
  • Exploiting genetic differences between normal and malignant cells
  • Targeting cancer cells
  • Multiple cancer fighting capabilities
  • Possibilities and restraints of ONYX-015
  • 10:20 DEVELOPING GENE MEDICINES

    Dr Alan Boyd

    Dr Alan Boyd, Director, Development, Ark Therapeutics

  • Moving from the research idea to the patient
  • Hitting the target site
  • Overcoming obstacles
  • Development of a cardiovascular gene medicine - TrinamTM
  • Development of a gene medicine for malignant Glioma - EG009
  • 11:00 Morning Coffee

    11:20 THERAPEUTIC ACTIVATION OF ENDOGENOUS GENES

    Dr John Girdlestone

    Dr John Girdlestone, Senior Scientist, Gendaq Ltd.

  • Engineered transcription factors
  • Gene repression
  • Gene activation
  • VEGF
  • Alternative splicing
  • Therapeutic angiogenesis
  • 12:00 TARGET VALIDATION

    Dr Julian Beesley

    Dr Julian Beesley, Director, Business Development, LifeSpan BioSciences

  • Gene selection
  • Molecular pathology
  • Target prioritization
  • Gene distribution
  • Potential toxicity
  • Evaluation in animal models

    Evaluation in human tissues

  • 12:40 Networking Lunch

    14:00 FROM THE BENCH TO THE PHARMACY

    Dr Claas Junghans

    Dr Claas Junghans, General Manager, Mologen

  • The importance of choosing the right patient
  • The perfect target
  • Getting the technology together
  • Persuading the authorities
  • Getting there first
  • And then making money…
  • 14:40 FROM CONCEPT TO COMMERCIALISATION

    Dr Samuel Wadsworth

    Dr Samuel Wadsworth, Vice President, Gene Therapy Initiative, Genzyme

  • The commercial process
  • Effective financing
  • Building an infrastructure
  • Technological barriers
  • Importance of getting to the market first
  • Problems with commercialising gene therapies
  • 15:20 Afternoon Tea

    15:40 REGULATIONS

    Dr Jayne Spink

    Dr Jayne Spink, Section Head, Genetic Science Policy, Gene Therapy Advisory Committee, Department of Health, UK

  • Clinical trials
  • Oversight of gene therapy
  • Ethical acceptability
  • Assessing the merits of gene therapy proposals
  • Obtaining regulatory approval
  • Current guidelines
  • 16:20 THE FUTURE OF GENE THERAPY

    Dr Barrie Carter

    Dr Barrie Carter, Executive Vice President & Chief Scientific Officer, Targeted Genetics

  • Potential for disease prevention
  • Erasing genetic diseases
  • Cost of eventual treatment
  • Getting products to the market
  • Future developments
  • Other therapeutic targets
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Marketing Gene Therapies
    Workshop

    Marketing Gene Therapies

    None
    26th February 2002
    , None

    Marketing Gene Therapies
    Workshop

    Marketing Gene Therapies

    The Hatton, at etc. venues
    26th February 2002
    London, United Kingdom

    Genetic vaccination: new hopes for vaccine development
    Workshop

    Genetic vaccination: new hopes for vaccine development

    The Hatton, at etc. venues
    1st March 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.